Jazz Pharmaceuticals (JAZZ) Long-Term Deferred Tax (2012 - 2026)

Jazz Pharmaceuticals has reported Long-Term Deferred Tax for 15 years, with the latest figure at $907.0 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax rose 57.71% year-over-year to $907.0 million; the trailing twelve-month figure through Mar 2026 stood at $907.0 million (up 57.71% YoY), and the FY2025 full-year result was $869.1 million, up 55.13% from the prior year.
• Long-Term Deferred Tax for Q1 2026 stood at $907.0 million, up from $869.1 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $907.0 million in Q1 2026, with the low at $314.7 million in Q1 2022.
• Average Long-Term Deferred Tax over 5 years is $535.0 million, with a median of $507.7 million recorded in 2024.
• Year-over-year, Long-Term Deferred Tax gained 0.1% in 2022 and soared 57.71% in 2026.
• Tracing JAZZ's Long-Term Deferred Tax over 5 years: stood at $376.2 million in 2022, then grew by 27.0% to $477.8 million in 2023, then gained by 17.25% to $560.2 million in 2024, then soared by 55.13% to $869.1 million in 2025, then advanced by 4.36% to $907.0 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $907.0 million (Q1 2026), $869.1 million (Q4 2025), and $846.2 million (Q3 2025), per Business Quant data.

Peer Comparison